Skip to content

Advertisement

  • Research
  • Open Access

Putative progressive and abortive feline leukemia virus infection outcomes in captive jaguarundis (Puma yagouaroundi)

  • 1Email authorView ORCID ID profile,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6 and
  • 7
Virology Journal201714:226

https://doi.org/10.1186/s12985-017-0889-z

  • Received: 17 August 2017
  • Accepted: 2 November 2017
  • Published:

Abstract

Background

Feline leukemia virus (FeLV) is an exogenous gammaretrovirus of domestic cats (Felis catus) and some wild felids. The outcomes of FeLV infection in domestic cats vary according to host susceptibility, virus strain, and infectious challenge dose. Jaguarundis (Puma yagouaroundi) are small wild felids from South and Central America. We previously reported on FeLV infections in jaguarundis. We hypothesized here that the outcomes of FeLV infection in P. yagouaroundi mimic those observed in domestic cats. The aim of this study was to investigate the population of jaguarundis at Fundação Parque Zoológico de São Paulo for natural FeLV infection and resulting outcomes.

Methods

We investigated the jaguarundis using serological and molecular methods and monitored them for FeLV-related diseases for 5 years. We retrieved relevant biological and clinical information for the entire population of 23 jaguarundis held at zoo. Post-mortem findings from necropsies were recorded and histopathological and immunohistopathological analyses were performed. Sequencing and phylogenetic analyses were performed for FeLV-positive samples. For sample prevalence, 95% confidence intervals (CI) were calculated. Fisher’s exact test was used to compare frequencies between infected and uninfected animals. P-values <0.05 were considered significant.

Results

In total, we detected evidence of FeLV exposure in four out of 23 animals (17%; 95% CI 5–39%). No endogenous FeLV (enFeLV) sequences were detected. An intestinal B-cell lymphoma in one jaguarundi was not associated with FeLV. Two jaguarundis presented FeLV test results consistent with an abortive FeLV infection with seroconversion, and two other jaguarundis had results consistent with a progressive infection and potentially FeLV-associated clinical disorders and post-mortem changes. Phylogenetic analysis of env revealed the presence of FeLV-A, a common origin of the virus in both animals (100% identity) and the closest similarity to FeLV-FAIDS and FeLV-3281 (98.4% identity), originally isolated from cats in the USA.

Conclusions

We found evidence of progressive and abortive FeLV infection outcomes in jaguarundis, and domestic cats were probably the source of infection in these jaguarundis.

Keywords

  • Retrovirus
  • FeLV-A
  • enFeLV
  • Intestinal B-cell lymphoma
  • qPCR
  • RT-qPCR
  • Wild felids

Background

Jaguarundis (Puma yagouaroundi) are small diurnal felids that have several unpatterned color morphs – brownish-black, gray and reddish-yellow fur – and are protected across most of their range. The species occurs at low densities and has a decreasing population in the wild, despite being widely distributed throughout South and Central America and occupying a broad range of habitats [1]. Mainly due to displacement from nature and, to a lesser extent, to captive breeding, jaguarundis are commonly found in zoos and similar captive settings in Brazil [2].

The feline leukemia virus (FeLV) is an exogenous, oncogenic, immunosuppressive gammaretrovirus that can establish persistent infections in domestic cats (Felis catus) [3]. The prevalence of FeLV ranges from 1% to 8% in healthy cats almost everywhere in the world and is usually higher when sick cats are included [4]. FeLV is naturally transmitted by oronasal exposure to virus-containing secretions, mainly saliva, but also in feces and urine [57]. The effects of FeLV are cytoproliferative diseases including lymphomas and myeloproliferative disorders; degenerative illnesses, such as anemia and leukopenia; and immunosuppressive diseases associated with opportunistic infections [3, 8].

FeLV infections tend to be rare or absent in many nondomestic felid species [914], except for the European wildcat (Felis silvestris silvestris), a species very closely related to the domestic cat, in which FeLV appears to be endemic [1517]. However, documentation of FeLV is becoming more common in wild felid species less closely related to the genus Felis, which highlights the omnipresent threat that FeLV represents to the conservation of wild felids worldwide. FeLV has been shown to represent a major threat to the survival of critically endangered populations of Iberian lynxes (Lynx pardinus) in Europe [18, 19] and to Florida panthers (Puma concolor coryi) in North America [20, 21]. In Brazil, antibodies against FeLV have been detected in two free-ranging pumas (Puma concolor) and two jaguarundis; FeLV DNA was detected in the following captive felids: an ocelot (Leopardus pardalis), an oncilla (Leopardus tigrinus) and two jaguarundis [2224].

For domestic cats, the detection of the structural viral protein FeLV p27 in serum or plasma is used as a marker of infection and, in most cases, as a parameter for viremia. The outcomes of FeLV infection vary according to infectious challenge dose, route of challenge, and possibly host susceptibility and virus strain. The classification of FeLV outcomes in the domestic cat has been refined using sensitive molecular assays that detect and quantify proviral FeLV DNA and viral FeLV RNA, in addition to traditional serological and virological methods [2530]. In this regard, the main host response categories of FeLV infection in domestic cats have been redefined as abortive, regressive, and progressive infection. In short, those cats that abort infection do not show any evidence of virus infection, except for seroconversion. Cats with regressive infection overcome viremia after an undetectable or transient initial phase by means of efficient cellular and humoral immune responses. These cats seroconvert, permanently harbor low to moderate FeLV proviral loads integrated in mononuclear cells, i.e., lymphocytes, and may or may not clear their plasma viral RNA loads [25, 27, 31]. Cats with progressive infection are constantly viremic, have low or no antibodies to FeLV, show elevated FeLV proviral and viral loads in peripheral blood cells and plasma and may develop FeLV-associated disease [25, 26, 28, 29].

In previous surveillance work, we detected FeLV infection in two captive-born jaguarundis (#1 and #4) as well as previous exposure to FeLV in two other captive-born jaguarundis (#2 and #22) among a population of 23 jaguarundis held at Fundação Parque Zoológico de São Paulo (FPZSP), Brazil [23]. Jaguarundis #1 and #4 tested positive for FeLV p27 antigen by sandwich ELISA. FeLV proviral DNA was detected in blood from both animals by quantitative real-time polymerase chain reaction (qPCR). The sampling for this previous study occurred between 2003 and 2004 (Table 1).
Table 1

Investigation of feline leukemia virus (FeLV) for captive jaguarundis (Puma yagouaroundi) and putative infection outcomes

Animal

Zoo registry (CAD)

 

FeLV serological tests

FeLV molecular testsa

enFeLV

Putative infection outcome

 

Antibody

Antigen

Viral RNA

Proviral DNA

Indirect ELISA p45b

Indirect ELISA p15Ec

Western blottingb

Sandwich ELISAb

Snap testb

IHCd (Tissues)

Whole blood or buffy coat

Saliva

Tissues

Whole blood or buffy coatb

Saliva

Tissues

Whole blood or buffy coat

#1

20761

Nege

Neg

Neg

Posf

Pos

Pos

Pos

Pos

Pos

Pos

Pos

Pos

Neg

Progressive

#2

20762

Posg

Nth

Pos

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Abortive with seroconversion

#3

21566

Neg

Neg

Neg

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Non-infected

#4

21810

Neg

Neg

Neg

Pos

Neg

Pos

Pos

Nt

Nt

Pos

Nt

Nt

Neg

Progressive

#5

22096

Neg

Neg

Neg

Neg

Neg

Neg

Neg

Nt

Neg

Neg

Nt

Neg

Neg

Non-infected

#6

23120

Neg

Nt

Neg

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Non-infected

#7

23851

Neg

Nt

Neg

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Non-infected

#8

23911

Neg

Nt

Neg

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Non-infected

#9

23956

Neg

Nt

Neg

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Non-infected

#10

24142

Neg

Nt

Neg

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Non-infected

#11

24189

Neg

Nt

Neg

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Non-infected

#12

24226

Neg

Nt

Neg

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Non-infected

#13

24227

Neg

Nt

Neg

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Non-infected

#14

24958

Neg

Neg

Neg

Neg

Neg

Neg

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Non-infected

#15

25244

Neg

Nt

Neg

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Non-infected

#16

25845

Neg

Nt

Neg

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Non-infected

#17

25846

Neg

Neg

Neg

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Non-infected

#18

26005

Neg

Nt

Neg

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Non-infected

#19

27088

Neg

Nt

Neg

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Non-infected

#20

27155

Neg

Nt

Neg

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Non-infected

#21

27156

Neg

Nt

Neg

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Non-infected

#22

27689

Neg

Nt

Pos

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Abortive with seroconversion

#23

28018

Neg

Nt

Neg

Neg

Neg

Nt

Neg

Nt

Nt

Neg

Nt

Nt

Neg

Non-infected

Positive results/total tested

1/23

0/6

2/23

2/23

1/23

2/4

2/23

1/1

1/2

2/23

1/1

1/2

0/23

 

aViral RNA and proviral DNA detection and quantification by RT-qPCR and qPCR, respectively [30]; enFeLV: investigation of endogenous proviral FeLV by qPCR [44]. bPreviously published test results [23]: Indirect ELISA – detection of serum or plasma antibodies against FeLV p45 [64]; Western blotting – detection of antibodies against FeLV proteins gp70, p58, p27, p15, and p12; blots are judged positive if they contain antibodies to at least three of these antigens [65]; sandwich ELISA – FeLV p27 antigen investigated in serum or plasma [66]; Snap test – FeLV p27 antigen measured in serum or fresh blood by Snap™ Combo FeLV Antigen/FIV Antibody Test Kit (IDEXX Laboratories, Inc., Westbrook, Maine 04092, USA); qPCR – proviral DNA detection in whole blood and buffy coat [30]. cIndirect ELISA – detection of plasma antibodies against the FeLV transmembrane protein p15E [32, 33]. Cutoff values were OD = 0.163. dIHC = FeLV antigen immunohistochemical analysis [35]. eNeg Negative test result. fPos Positive test result. gPos in indirect ELISA for detection of antibodies against FeLV p45 was 94% of the positive control used. hNt not tested

By analogy, we hypothesized here that FeLV infection in P. yagouaroundi mimics the main outcomes observed for the domestic cat. Thus, the aim of this study was to perform additional serological and molecular tests and monitor the population of jaguarundis at FPZSP for FeLV infection and development of FeLV-related diseases for 5 years (2003–2007).

Methods

Animals and sample collections

We retrieved relevant biological and clinical information for the entire population of 23 jaguarundis held at FPZSP, from birth or admission of the animals into the zoo until 2007. Most animals were mature adults (n = 16), five were immature and two were geriatric; kittens were absent. Three jaguarundis were wild born, while 20 were captive born at FPZSP. Six females (two of wild origin) and three zoo-born males were reproductively active. Eleven animals from the population were full siblings, and 16 were half siblings. The females (n = 9) averaged 4.28 ± 0.57 kg in body weight, and the males (n = 14) averaged 5.08 ± 0.49 kg in body weight. Detailed biological data such as age, sex, weight, origin (captive or wild born) and the parental history for the 23 jaguarundis are presented in Table 2.
Table 2

Biological data of the studied population of 23 jaguarundis (Puma yagouaroundi)

Animal

CAD

Sex

Weight (kg)

Origin

Sampling date

Date of birth/zoo entrancea

Age in months

Age groupb

Father (CAD)

Mother (CAD)

#1

20761

male

5.130

captive born

23/06/2004

24/06/1993

132

geriatric

19914

15245

#2

20762

female

4.505

captive born

26/11/2003

24/06/1993

125

geriatric

19914

15245

#3

21566

female

4.835

wild born

10/12/2003

01/05/1994a

115

mature adult

wild born

wild born

#4

21810

male

3.985

captive born

23/06/2004

27/12/1994

114

mature adult

wild born

wild born

#5

22096

male

5.165

captive born

23/06/2004

17/08/1995

106

mature adult

19914

15245

#6

23120

female

5.320

captive born

26/11/2003

09/03/1997

80

mature adult

17406

22097

#7

23851

female

4.250

captive born

03/12/2003

20/06/1998

66

mature adult

17406

20762

#8

23911

male

5.505

captive born

10/12/2003

15/08/1998

64

mature adult

unknownc

18544

#9

23956

male

5.260

captive born

10/12/2003

14/09/1998

63

mature adult

17406

unknownc

#10

24142

female

4.315

wild born

26/11/2003

01/12/1998a

59

mature adult

wild born

wild born

#11

24189

male

5.925

captive born

26/05/2004

05/01/1999

64

mature adult

19914

23120

#12

24226

male

4.925

captive born

25/05/2004

16/02/1999

63

mature adult

19914

21566

#13

24227

male

4.920

captive born

03/12/2003

16/02/1999

58

mature adult

19914

21566

#14

24958

male

5.300

captive born

30/06/2004

02/03/2000

51

mature adult

23119

21566

#15

25244

female

3.685

captive born

26/11/2003

05/11/2000

36

mature adult

23956

24142

#16

25845

male

5.665

captive born

26/05/2004

06/04/2001

37

mature adult

22096

23851

#17

25846

male

4.490

captive born

26/05/2004

06/04/2001

37

mature adult

22096

23851

#18

26005

female

4.105

wild born

19/11/2003

12/06/2001a

29

mature adult

wild born

wild born

#19

27088

male

4.765

captive born

03/12/2003

07/01/2002

23

immature adult

23119

25244

#20

27155

male

4.755

captive born

10/12/2003

20/02/2002

22

immature adult

23956

24142

#21

27156

female

4.090

captive born

26/11/2003

20/02/2002

21

immature adult

23956

24142

#22

27689

male

5.325

captive born

03/12/2003

01/09/2002

15

immature adult

22096

23851

#23

28018

female

3.410

captive born

19/11/2003

15/03/2003

8

immature adult

21810

20762

Notes: FeLV-infected (#1, #4) and FeLV seropositive (#2, #22) jaguarundis are identified in bold. aFor the wild-born jaguarundis (#3, #10 and #18), the dates refer to entrance in the zoo as their dates of birth are unknown. bImmature adults (n = 5) were defined as jaguarundis in the age range of 6 months ≤ age < 24 months for males and 6 months ≤ age < 36 months for females; mature adults (n = 16) were defined as those in the age range of 24 months ≤ age < 10 years (120 months) for males and 36 months ≤ age < 10 years for females; geriatric jaguarundis (n = 2) were those aged ≥10 years for both sexes. cFor two captive-born jaguarundis (#8, #9), the identities of the father and the mother, respectively, were not available

For hematological analysis, several laboratories were used over time, and registries of results from the animals were not completed and standardized. All jaguarundis were vaccinated regularly against feline herpesvirus 1 (FHV-1), feline calicivirus (FCV), feline parvovirus (FPV) and rabies lyssavirus. We monitored the potential development of FeLV-related diseases through clinical data provided by the veterinarian staff at the zoo and registered at the zoo archives.

Serological and molecular FeLV tests were performed, in addition to those previously published [23], using samples that had been previously obtained or additional samples collected throughout the observation period. FeLV tests previously performed included p27 FeLV antigen detection by a sandwich ELISA and the commercial immunoassay Snap™ Combo FeLV Antigen/FIV Antibody Test Kit (IDEXX Laboratories Inc., Westbrook, ME, USA), detection of antibodies against the recombinant non-glycosylated form of the FeLV gp70 surface glycoprotein (p45) by indirect ELISA, detection of antibodies against FeLV p12, p15, p27, p58, and gp70 antigens by Western blot and detection of FeLV proviral DNA by real-time PCR. We investigated the presence of antibodies to FeLV transmembrane protein p15E in serum samples from six jaguarundis (#1, #3, #4, #5, #14 and #17) using the previously described assay [32, 33].

Six jaguarundis (#1, #2, #4, #5, #10 and #14) died between 2005 and 2008 and underwent necropsy at the zoo; for these jaguarundis, relevant clinical and post-mortem findings from necropsies were recorded, and several tissues were collected for analyses. Fragments of tissues from these animals were fixed in 10% formalin, embedded in paraffin wax and sectioned. The sections were stained with hematoxylin-eosin (HE) on glass slides for histopathological analyses. Tissue specimens from animals #1 and #5 (bone marrow, mesenteric lymph node and spleen) were also stored at ≤ −70 °C. A saliva specimen from animal #1 was collected at first sampling using a sterile cotton swab immersed in virus transport media, which consisted of phosphate-buffered saline (PBS) balanced salt solution supplemented with 0.5% bovine albumin (BSA), antimicrobial agents (200 U/mL penicillin G, 200 U/mL streptomycin, 25 μg/mL fungizone and 6 μg/mL gentamycin) and was kept at ≤ −70 °C. No additional material could be obtained from animal #2.

Immunohistology

To clarify the histogenesis of an intra-abdominal mass of tissue that developed in jaguarundi #5, we performed immunohistologic assays by the streptavidin-biotin-peroxidase complex technique with a commercial immunoperoxidase kit (LSAB kit, Dako, Glostrup, Denmark) according to the manufacturer’s protocol. We used silanized microscope slides to produce histologic slides, which were processed by usual deparaffination techniques in xylol and hydrated in alcohols (absolute, 95%, 70%, and distilled water). A microwave antigen retrieval technique using EDTA buffer, pH 9.0, was applied [34]. The sections were incubated overnight at 4 °C with primary antibodies against the T-cell marker CD3 (rabbit polyclonal antibodies A0452; Dako; diluted 1 in 500), the B-cell marker CD79 (mouse monoclonal antibodies; clone HM57; M7051; Dako; diluted 1 in 500), and vimentin (mouse monoclonal antibodies; M0725; Dako; diluted 1 in 100) as well as antibodies against proliferating cell nuclear antigen antibodies (PCNA) (mouse monoclonal antibodies; M0879; Dako; diluted 1 in 800). For all reagents, negative controls were generated by substituting the primary antibody with a class-matched immunoglobulin. These procedures were conducted using the logistics of the Department of Pathology, School of Veterinary Medicine and Animal Sciences, University of São Paulo (USP), São Paulo, SP, Brazil.

We investigated the presence of FeLV antigens in several paraffin-embedded tissues from the deceased jaguarundis #1, #4, #5 and #14. This investigation was carried out using the methods and logistics of the Institute of Veterinary Pathology, University of Giessen, Giessen, Germany [35].

Extraction of nucleic acids

Total nucleic acid (TNA) was extracted from 100 μL of EDTA-anticoagulated whole blood or buffy coat or from 200 μL of EDTA-anticoagulated plasma using the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche Diagnostics, Rotkreuz, Switzerland). TNA was eluted into 100 μL of elution buffer and stored at −70 °C until PCR testing was performed. RNA was extracted from the saliva, plasma samples collected from jaguarundi #1 and from serum samples from jaguarundis #1 and #4 using the QIAmp® Viral RNA Mini Kit (Qiagen). gDNA and RNA were extracted from tissues (bone marrow, mesenteric lymph node and spleen) from animals #1 and #5 upon necropsy, as previously described [36, 37]. During all extractions, negative controls consisting of 100 μL of PBS were concurrently prepared with each batch of samples to monitor for cross-contamination.

Molecular tests for FeLV

FeLV viral RNA loads and proviral loads were investigated using real-time RT-PCR and PCR and primers targeting the U3 region of exogenous FeLV, as previously described [30]. For tissue samples, the total copy numbers detected per reaction were normalized to the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene as described [38].

FeLV subgroups A, B and C were investigated in the bone marrow, mesenteric lymph node, and spleen of the jaguarundi #1 and in the serum and plasma of jaguarundi #4 by conventional PCR using the FeLV-A specific primers RB59 and RB17; the FeLV-B specific primers RB53 and RB17 and the FeLV-C specific primers RB58 and RB47 as described [39, 40].

Feline immunodeficiency virus (FIV) serology and molecular assays

Serum from jaguarundi #5 was tested for the presence of antibodies against feline immunodeficiency virus (FIV) using a commercial immunoassay Snap™ Combo FeLV Antigen/FIV Antibody Test Kit (IDEXX Laboratories) and by Western blotting, as described [41]. FIV real-time and conventional RT-PCR were performed from whole blood from jaguarundi #5, as previously described [42, 43].

Endogenous FeLV-like sequences (enFeLV) PCR

TNA samples from the whole blood or buffy coat of all 23 jaguarundis were tested for the presence of endogenous FeLV (enFeLV) by the three qPCR assays enFeLV-U3–1, enFeLV-U3–2, and enFeLV-env, as previously described [44].

Sequencing of FeLV env from jaguarundis #1 and #4

FeLV env sequences were analyzed for the FeLV-positive jaguarundis #1 and #4 from TNA of previously collected buffy coats. For comparison, a second sequence obtained from bone marrow of animal #1 was analyzed 1.4 years later, at the time of euthanasia. For the analysis of the full-length FeLV env sequences, genomic DNA from these samples was amplified using PCR with the primers 5847F (5′ ACATATCGTCCTCCTGACCAC 3′) and 8197R (5′ GAAGGTCGAACCCTGGTCAACT 3′) [43], yielding an approximately 2´370 bp product. To ensure high-fidelity amplification, the PCR was performed using Phusion polymerase and HF buffer (Finnzyme, Ipswich, UK). PCR products were sequenced by Microsynth (Balgach, Switzerland) after purification using the GenElute PCR Clean-Up Kit (Sigma, Fluka GmbH, Buchs, Switzerland). The jaguarundi FeLV-A env sequence was submitted to GenBank [KR349469].

Phylogenetic analysis

Phylogenetic analyses were conducted using MEGA version 6 [45]. The FeLV env sequences were aligned using CLUSTAL W [46]. Bootstrap support (1000 replicates) was calculated by the neighbor-joining (NJ) [47] and maximum parsimony (MP) [48] methods, and results >70% were considered significant [49]. The MP tree was obtained using the subtree-pruning-regrafting (SPR) algorithm [48] with search level 1 in which the initial trees were obtained by the random addition of sequences (10 replicates). All positions containing gaps and missing data were eliminated from the dataset (complete deletion option).

Statistics

For sample prevalence, 95% confidence intervals (CI) were calculated. Fisher’s exact test was used to compare frequencies between infected and uninfected animals. P-values <0.05 were considered significant.

Results

Clinical data of all 23 jaguarundis

The population of jaguarundis kept at FPZSP from 2003 to 2007 consisted of 23 captive jaguarundis. The animals presented good general condition at sampling. Twenty animals presented discrete to moderate oral disorders, including one or more of the following conditions: gingivitis, presence of tartar, periodontitis, tooth loss and/or fractured teeth. No oral disorders were registered in three immature adults, #19, #21 and #23. At least once during the experiment, 15 animals presented episodes of diarrhea, 11 jaguarundis demonstrated transitory weight loss and three suffered from dermatological disorders, such as alopecia; for all these clinical conditions, the underlying causes of the problems were unknown. Despite regular deworming, intestinal parasites were detected in 18 animals during the study period. In hematological analysis, most animals (n = 16) showed some degree of leukopenia (marked: n = 1; mild: n = 8) and leukocytosis (marked: n = 2; mild: n = 5). Jaguarundi #1, which was FeLV positive, and jaguarundi #2, which was FeLV seropositive, showed mild transient leukocytosis. Several (n = 12) animals showed mildly increased packed cell volume (PCV) and two showed markedly increased PCV in at least one sampling. Jaguarundis #1 and #2 showed mildly increased PCV, and jaguarundi #22, which was FeLV seropositive, showed a markedly increased PCV. The increased PCV could be due to dehydration as the animals had been fasted before immobilization.

Deceased animals

Six jaguarundis (#1, #2, #4, #5, #10 and #14) in the investigated population died from 2005 to 2008. Jaguarundi #1 was euthanized 1.4 years after being diagnosed with FeLV infection [23]. This jaguarundi was euthanized because the zoo could not keep it segregated under good ethological conditions, although the animal was in good clinical condition. Jaguarundi #5 developed a large intra-abdominal mass of tissue about 1 year after testing negative for FeLV. After clinical and ultrasonographic examinations, the animal underwent laparotomy for excision of the mass and died 3 days after surgery due to clinical deterioration. Animals #2, #4, #10 and #14 died naturally during the period of study. For the six deceased animals, clinical conditions and main post-mortem findings are presented in Table 3.
Table 3

Clinical and necroscopic findings of five jaguarundis (Puma yagouaroundi) that died between 2005 and 2008

Animal identification

Origin

Sex

Age category at death

Clinical condition before death

Main post-mortem findings

#1

Captive born

Male

Geriatric

Clinically healthya

Hepatitis, pulmonary edema and emphysema, splenic lymphoid depletion, renal tubular degeneration, renal medullary fibrosis, glomerulonephritis, obesity, muscular atrophy of hind limbs

#2

Captive born

Female

Geriatric

Weight loss

Severe membranous proliferative glomerulonephritis, parasitic hemorrhagic enteritis, hepatic steatosis, cardiomyopathy

#4

Captive born

Male

Mature

Weight loss, vomiting, anorexia, diarrhea

Hepatitis, pulmonary infarction, splenic hypoplasia, decreased number and size of spleen germinal centers, membranous proliferative glomerulonephritis, enteritis, adrenal necrosis

#5

Captive born

Male

Mature

Malignant lymphoma, weight loss and clinical deterioration

Hepatitis, pulmonary emphysema, splenic lymphoid depletion and follicular hypoplasia, membranous proliferative glomerulonephritis, renal tubular degeneration, severe enteritis, malignant neoplasia of round cells (intestinal B-cell lymphoma)

#10

Wild

Female

Mature

Weight loss, circulatory shock, convulsion

Severe interstitial histiocytic bronchopneumonia associated with the presence of intralesional protozoa; intense multifocal and coalescent pancreatic fibrosis

#14

Captive born

Male

Mature

Weight loss, diarrhea

Colitis, enteritis, gastritis, lymphopathy, inguinal herniation, ulcers on the tongue

aJaguarundi #1 was recognized to be FeLV positive and shedding FeLV in its saliva; thus, the animal was euthanized while clinically healthy to prevent further spreading of FeLV infection

Indirect ELISA for p15E

Antibodies against p15E antigen were not detected to a level that is considered positive for privately owned domestic cats and the results from all the jaguarundis tested (#1, #3, #4, #5, #14 and #17) were negative (Table 1).

FeLV-negative B-cell lymphoma in jaguarundi #5

The excised mass of tissue from jaguarundi #5 weighed approximately 0.25 kg and affected all layers of the wall of the jejunum. In addition, several small foci were present across the mesentery. There was multifocal necrosis as well as intense reactional fibrosis and proliferation of round cells arranged in dense blocks limited by delicate conjunctive septa. The cells were neoplastic and malignant and presented anisokaryosis, anisocytosis, and a high mitotic index. The tumor was found to be an intestinal B-cell lymphoma, as the cells stained positive for a B-cell marker (CD79) but not a T-cell marker (CD3) by immunohistology. No FeLV RNA or provirus was detected in the tissues collected upon necropsy, including tumoral tissues, bone marrow, mesenteric lymph nodes and spleen, and no FeLV antigens were detected in paraffin-embedded tissues by immunohistological analysis (Table 1). Because B-cell lymphomas can also be associated with FIV infection, jaguarundi #5 was tested for FIV by serology and PCR. The animal tested negative for antibodies to FIV in the commercial assay. In the FIV Western blot, one band against p24 was detectable.

Molecular detection of FeLV-A in two jaguarundis (#1 and #4)

FeLV RNA and proviral DNA were detected in two out of the 23 animals, namely, jaguarundis #1 and # 4. From jaguarundi #1, a saliva sample was available; it was FeLV RNA positive, indicating shedding of FeLV at the time of sampling. FeLV was also demonstrated in the plasma sample collected at a second sampling from jaguarundi #4 upon necropsy 1.4 years later, indicating persistent antigenemia in this animal. For jaguarundis #1 and # 4, respectively, the absolute copy numbers of proviral DNA were 4.26 × 107 and 3.49 × 107 copies of DNA/mL of buffy coat; the absolute copy numbers of viral RNA were 2.63 × 108 and 2.97 × 109 copies of RNA/mL of serum. The results from all FeLV tests are presented in Tables 1 and 4. Furthermore, FeLV could be demonstrated in the tissue samples collected at necropsy from jaguarundi #1, and FeLV antigens were confirmed by immunohistological analysis of paraffin-embedded tissue samples from deceased jaguarundis #1 and #4. For both jaguarundis, #1 and #4, FeLV-A was the only FeLV subtype identified; no FeLV-B or FeLV-C was detected.
Table 4

Feline leukemia virus (FeLV) viral and proviral loads from jaguarundis (Puma yagouaroundi) presenting putative progressive infection

Animal

Viral load (RNA) by RT-qPCR

Proviral load (DNA) by qPCR

 

Seruma

Salivab

Mesenteric lymph nodec

Bone marrowc

Spleenc

Buffy coata

Salivab

Mesenteric lymph nodec

Bone marrowc

Spleenc

#1

2.63 × 108

1.65 × 105

1.31 × 100

4.74 × 100

1.74 × 100

4.26 × 107

1.88 × 103

2.64 × 10−1

5.61 × 10−1

3.68 × 10−1

#4

2.97 × 109

Ntd

Nt

Nt

Nt

3.49 x 107

Nt

Nt

Nt

Nt

aTotal copy numbers of FeLV RNA or provirus detected per mL of serum or buffy coat, respectively. bTotal copy numbers detected per reaction (5 μL of total nucleic acid – TNA); no absolute quantification was possible since the input saliva volume from the swab sample was not known. cTotal copy numbers detected per reaction in tissue samples, normalized to the copy number of the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene. dNt not tested; samples were not available

No detection of enFeLV

No enFeLV was detected in the blood or buffy coat samples from any of the 23 jaguarundis.

Sequencing and phylogenetic analysis of the jaguarundi FeLV-A

Sequencing of the FeLV isolate retrieved from jaguarundis #1 and #4 revealed one conserved env sequence with 100% identity. Similarly, no sequence variation could be detected between the virus present in buffy coat from jaguarundi #1 and the virus detected in bone marrow at the time of euthanasia 1.4 years later in the same animal (100% identity). Phylogenetic analysis conducted by the MP and NJ methods revealed clustering of the jaguarundi env with several North American virus strains showing the closest similarity to FeLV-FAIDS [M18247] and FeLV-3281 [L25631], with 98.4% identity (Fig. 1). When the env surface unit from the FeLV detected in jaguarundis was compared with those found in Iberian lynxes [EU293175 to EU293194], a sequence identity of approximately 97% was obtained (data not shown).
Fig. 1
Fig. 1

Analysis of the evolutionary relationship using the maximum parsimony (MP) method with 20 sequences. a Relationships at the DNA level. Tree #1 out of the 2 most parsimonious trees (length = 1616) is shown. The consistency index is (0.622642), the retention index is (0.696970), and the composite index is 0.515827 (0.433962) for all sites and parsimony-informative sites (in parentheses). There were a total of 1837 positions in the final dataset. b Relationships at the protein level. The most parsimonious tree, with length = 637, is shown. The consistency index is (0.750000), the retention index is (0.747664), and the composite index is 0.620901 (0.560748) for all sites and parsimony-informative sites (in parentheses). There were a total of 605 positions in the final dataset. The percentages of replicate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) are shown next to the branches. The tree is drawn to scale, with the length being relative to the number of changes over the entire sequence. The MP tree was obtained using the subtree-pruning-regrafting (SPR) algorithm with search level 1 in which the initial trees were obtained by the random addition of sequences (10 replicates). All positions containing gaps and missing data were eliminated. Analyses were conducted in MEGA 6 [4447, 63]

Discussion

We detected evidence of FeLV exposure in four (#1, #2, #4 and #22) out of 23 jaguarundis in the FPZSP (17%; 95% CI 5–39%). The remaining 19 jaguarundis were negative for FeLV in all serological and molecular tests performed. The population of jaguarundis presented clinical disorders that were common at FPZSP, as in any other captive setting in Brazil [2, 12], and could be associated with a multitude of causes. Although the FeLV-positive jaguarundis also presented some conditions that could be related to FeLV [8], our data were insufficient to prove a causal association.

Two captive-born male jaguarundis, the geriatric #1 and the mature adult #4, presented serological and molecular FeLV test results similar to the progressive FeLV infection outcome in domestic cats [25]. Jaguarundis #1 and #4 were both antigenemic. Antigenemia is usually used as a measure for viremia in domestic cats and is consistently found in domestic cats with a progressive FeLV infection outcome [26, 28]. Additionally, blood, buffy coat, serum and tissue samples from both jaguarundis were positive for FeLV proviral DNA and viral RNA with high proviral and viral loads, respectively (Table 4). While the presence of proviral DNA attests to the integration of provirus into blood cells, the detection of viral RNA usually indicates replicating virus. Once the infection outcome has been established, high proviral and FeLV RNA loads are characteristically found in cats with progressive infection, while low loads are detected in cats with regressive infection that are provirus positive but not viremic at the time [25, 29, 50]. FeLV proviral and viral RNA loads were measured in the two FeLV-positive jaguarundis #1 and #4. Comparison of the FeLV tissue loads of jaguarundi #1 revealed loads similar to those reported earlier for domestic cats with progressive infection using identical methods. Viral RNA loads in serum from the two FeLV-positive jaguarundis were comparable to those described earlier in persistently antigenemic cats [30]. The viral RNA load in the clinically healthy jaguarundi #1 was slightly lower than that in jaguarundi #4, which showed weight loss, vomiting, anorexia and diarrhea before death. This is also similar to previous findings from a study in cats, comparing viremic healthy and viremic ill cats [51]. Moreover, consistent with findings in domestic cats with a progressive FeLV infection, no antibodies to FeLV antigens were detected in jaguarundis #1 and #4.

FeLV RNA and FeLV provirus were also detected in the saliva of jaguarundi #1. This finding is indicative of virus shedding; thus, jaguarundi #1 was a potential source of FeLV infection to other felids. Jaguarundi #1 was euthanized in good clinical condition as a biosafety measure. However, upon necropsy, histopathologic evaluation revealed splenic lymphoid depletion and muscular atrophy of the hind limbs; these findings may be associated with immunosuppression and neurological impairment in this animal. Jaguarundi #4 died presenting weight loss and gastrointestinal disorders including vomiting, anorexia and diarrhea. Histopathology revealed splenic alterations and evidence of enteritis (Table 3). Although these conditions are commonly associated with FeLV in domestic cats, it was not possible to ascertain whether they were caused by FeLV infection in this case.

Two captive-born jaguarundis, #2 and #22, presented test results similar to those reported for domestic cats with abortive FeLV infection and seroconversion as the only marker of FeLV exposure [28]. The female jaguarundi #2 had a history of direct contact with the two jaguarundis with progressive FeLV infection, #1 and #4: she was a sibling of jaguarundi #1 and had mated with the male #4. This would explain how she was exposed to FeLV, either at the same time as her sibling #1 or during mating with #4. Subsequently, jaguarundi #2 gave birth to jaguarundi #23, who did not show any signs of FeLV exposure (Tables 1, 2, 4). This may well be the case, since the mother, #2, had developed an antibody response and probably had never shed FeLV (abortive infection). It is unknown for how long and at what virus challenge conditions jaguarundi #2 was exposed, as animals were naturally and not experimentally infected in the present study. Overall, we speculate that jaguarundi #2 developed an abortive FeLV infection for similar (and possibly several) reasons that may drive FeLV abortive infections in some domestic cats. The parents of male jaguarundi #22 were the FeLV-negative male jaguarundi #5 and the female #7. Thus, it is unknown at what time point jaguarundi #22 was exposed to FeLV.

Overall, we provide evidence of progressive and abortive FeLV infection in P. yagouaroundi. Similar results have been found in Florida panthers (Puma concolor coryi), which belong to the felid lineage 6 (genus Puma), the same phylogenetic lineage as the jaguarundis [52]. In Florida panthers, infection outcomes resembled those of domestic cats with progressive, regressive and abortive infection (previously persistent, regressive, and latent infection) [20, 21]. We speculate that FeLV infection in jaguarundis is similarly unpredictable, and it is influenced for the same diverse aspects cited above for domestic cats.

Complimentary to the fact that FeLV causes various tumors in domestic cats [53], the literature has reported a FeLV-associated multicentric T-cell lymphoma in a captive non-domestic cheetah (Acinonyx jubatus) [54] and non-FeLV-associated T- and B-cell lymphomas in geriatric African lions (Panthera leo) [55]. These data motivated the search for possible FeLV involvement in the appearance of the neoplastic intra-abdominal mass in jaguarundi #5. Although jaguarundi #5 had not shown any evidence of FeLV infection intra vitam (Table 1), we further investigated whether FeLV antigens or proviruses were present in intestinal lymphoid cells and whether these cells produced FeLV viral RNA locally without it entering the bloodstream – as would be expected in a case of sequestered FeLV infection [4]. However, no FeLV antigens were detected by immunohistochemistry and no FeLV provirus or viral RNA were detected by molecular assays. Infection with FIV, which is a lentivirus associated with lymphomagenesis in domestic cats [56], was not detected by the commercial immunoassay, and only antibodies specific to FIV p24 capsid proteins were detected by Western blot, which may be indicative of an early or very late FIV infection or may have resulted from unspecific cross-reactivity. The FIV RT-PCR assays performed from whole blood were negative; however, this may be due to low viral loads or lack of specificity of the assays due to sequence diversity of different FIV isolates. In conclusion, jaguarundi #5 had developed a non FeLV-associated intestinal B-cell lymphoma; involvement of FIV in the development of the neoplasia cannot completely be ruled out.

Notably, a spleen sample from jaguarundi #5 had been previously analyzed for the presence of the FeLV receptor fTHTR1, which permits the virus to enter the cell. The fTHTR1 complementary DNA (cDNA) from that animal had shown 99% nucleotide and amino acid identity to the fTHTR1 cDNA sequences of the domestic cat and other wild felid species, such as the lynx (Lynx pardinus), African lion (P. leo bleyenberghi), Asiatic lion (P. leo persica), and European wildcat (F. silvestris silvestris) [57]. In addition, fTHTR1 was quantified by real-time PCR in a few tissues from two jaguarundis where tissue was available (the viremic jaguarundi #1 and jaguarundi #5, which developed a tumor, but was not FeLV-infected).These limited results showed no significant difference between the fTHTR1 tissue loads in cat and jaguarundi tissue (results not shown). However, it also needs to be mentioned that the real-time PCR assay was designed for the domestic cat THTR1 and not the jaguarundi THTR1. Two-point mutations can be found in the region of the assay: one-point mutation in the middle of the forward primer and one in the probe. Thus, although similar fTHTR1 expression levels were found in jaguarundi tissue compared with cat tissue, we cannot exclude differences in the efficiency of the real-time PCR assay. These findings support the perspective that the first phase of the FeLV virus cycle – viral entry – might be similar among domestic cats and other wild felid species.

We did not detect enFeLV in the jaguarundis by qPCR. This is consistent with earlier data [58] in which enFeLV was not detected in jaguarundis. Accordingly, FeLV-B, which has greater pathogenicity than FeLV-A in domestic cats and arises by recombination of exogenous FeLV-A with enFeLV sequences [59], was not found in the two FeLV-positive jaguarundis #1 and #4. Moreover, the highly virulent FeLV-C was not detected. In FeLV-infected Iberian lynxes, enFeLV sequences were also not detected, but their FeLV-A variants were shown to be highly virulent, suggesting that the mechanisms inducing disease in these wild felids might be distinct from those in domestic cats [19].

The env sequence obtained from the FeLV infections of jaguarundis #1 and #4 [KR349469] clustered with the highest identity with the FeLV-FAIDS and FeLV-3281 strains, which represent members of a highly conserved group of horizontally transmitted, minimally pathogenic FeLV-A present in all naturally occurring infections in domestic cats. Both FeLV strains were originally isolated from cats in the United States of America (USA) [60, 61]. Interestingly, the surface unit of the env sequence of FeLV detected in the jaguarundis also showed 97% identity to those of the env gene of FeLV isolated from the critically endangered Iberian lynxes [EU293175 to EU293194] in Spain, whose small wild population suffered from an outbreak of FeLV with several deaths [18].

Both PCR-positive jaguarundis, #1 and #4, were infected with a FeLV with an identical env sequence, indicating a common origin of the virus. It is unknown at what time point each of the jaguarundis became infected. The reproductive success achieved for jaguarundis in captivity is probably a result of the breeding program conceived for small felids at FPZSP [62] and a number of measures for improving the well-being of the animals, including the location of the jaguarundi enclosures in an isolated and forested area of the zoo away from the public. Nonetheless, domestic cats commonly are seen invading the zoo, especially the more isolated areas, and they were probably the source of infection of FeLV for the jaguarundis. Domestic cats are the main reservoir for FeLV worldwide and greatly outnumber FeLV-infected wild felids. Given this, it is prudent to prevent the presence of domestic cats in nature reserves, zoos and other settings with captive wild felids and to reinforce the importance of control measures for FeLV in domestic cats, such as testing and vaccination.

A severe FeLV outbreak occurred in a previously naïve population of Florida panthers (Puma concolor coryi) in North America from 2002 to 2005 in which five FeLV antigen-positive panthers died [20, 21]. During a six-month period in 2007, six provirus-positive antigenemic Iberian lynxes (Lynx pardinus) died in Spain [18, 19]. In both situations, FeLV vaccination programs were initiated. We recommend safe recombinant subunits or inactivated FeLV vaccines for captive jaguarundis, especially considering that invading domestic cats, potential sources of infection, are a frequent problem faced by zoos. In addition, we recommend the inclusion of FeLV testing in breeding programs for jaguarundis.

Conclusions

Our findings support our hypothesis that FeLV infection in P. yagouaroundi mimics the outcomes observed for the domestic cat. In addition, we found phylogenetic evidence that domestic cats may have been the source of the FeLV-A infection of the jaguarundis. Despite the minimal pathogenicity of FeLV-A for domestic cats, this virus may represent a threat to the jaguarundi population, and regular FeLV testing and vaccination are encouraged.

Declarations

Acknowledgments

We are deeply indebted to all veterinarians and staff of Fundação Parque Zoológico de São Paulo (FPZSP). We thank J. D. L. Fedullo, S. H. R. Corrêa, M. G. Bueno, A. P. Setzer, R.H.F. Teixeira, D.M. Soares, H. S. Barbosa, P. M. Bressan and J. B. Cruz for providing all the necessary support. The laboratory work was performed using the logistics of the Department of Pathology at School of Veterinary Medicine and Animal Sciences, University of São Paulo (USP); the Center for Clinical Studies at the Vetsuisse Faculty, University of Zurich; and the Institute of Veterinary Pathology, University of Giessen. We thank Dr. Maria Lúcia Zaidan Dagli, Patrícia Matsuzaki, Dr. M. Meli, Dr. V. Cattori, E. Gönczi, T. Meili, and B. Weibel for the excellent laboratory assistance and helpful support. We are grateful to Fábio Okutani Kozu, Míriam Halásk Vask, and Leandro Badiglian for ultrasonography performed at FPZSP. We also express our appreciation to the National Center of Research and Conservation of Carnivores (CENAP) of the Chico Mendes Institute for Conservation of Biodiversity (ICMBio), the Brazilian Institute of Environment and Renewable Natural Resources (IBAMA).

Funding

This work was supported by grants of Coordination for the Improvement of Higher Education Personnel (CAPES) and the Post-Graduate Pro-Rector from USP in Brazil and the International Relations Office from the University of Zurich in Switzerland. Partial writing of this manuscript work was also supported by the São Paulo Research Foundation (Fapesp) (grant 2013/12253–0). The funding bodies had no specific role in the design of the study, collection, analysis, and interpretation of data.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article.

Authors’ contributions

CF, JLCD and RHL concepted and designed the study. CF and MCM handled, sampled, and retrieved data from jaguarundis at zoo. CF and KHH conducted the serological and molecular tests. CF, JLCD, LNT and MR performed the histopathological and immunohistopathological analyses. KHH conducted the sequencing and phylogenetic analyses. All of the authors drafted and approved this version of the manuscript.

Ethics approval and consent to participate

All procedures were approved by the Bioethics Commission of the School of Veterinary Medicine and Animal Sciences of the University of São Paulo (protocol no. 256/2003) and the Convention on International Trade in Endangered Species (CITES) (permit nos. 08BR001932/DF and 08BR001931/DF).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Institute of Biosciences, Department of Microbiology and Immunology, São Paulo State University (UNESP), Campus Botucatu, Rua Professor Doutor Antonio Celso Wagner Zanin SN, Botucatu, São Paulo, 18618-689, Brazil
(2)
Vetsuisse Faculty, Clinical Laboratory and Center for Clinical Studies, University of Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland
(3)
School of Veterinary Medicine and Animal Sciences, Department of Pathology, University of São Paulo (USP), Av. Prof. Orlando Marques de Paiva 87, São Paulo, 05508-270, São Paulo, Brazil
(4)
Fundação Parque Zoológico de São Paulo (FPZSP), Av. Miguel Stéfano 4241, São Paulo, São Paulo, 04301-905, Brazil
(5)
School of Veterinary Medicine and Animal Sciences, Veterinary Hospital (HOVET), University of São Paulo (USP), Av. Prof. Orlando Marques de Paiva 87, São Paulo, 05508-270, São Paulo, Brazil
(6)
Institute of Veterinary Pathology, University of Giessen, Frankfurter Strasse 96, Giessen, 35392, Germany
(7)
Vetsuisse Faculty, Clinical Laboratory and Center for Clinical Studies, University of Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland

References

  1. Caso A, Oliveira T, Carvajal SV. Herpailurus yagouaroundi. In: The IUCN red list of threatened species; 2015. http://www.iucnredlist.org/details/9948/0. Accessed 23 June 2017.Google Scholar
  2. Adania CH, Silva JCR, Felippe PAN. Carnivora – Felidae (Onça, Suçuarana, Jaguatirica e Gato-do-Mato). In: Cubas ZS, Silva JCR, Catão-Dias JL, editors. Tratado de animais selvagens: medicina veterinária. São Paulo: Roca; 2014. p. 779–818.Google Scholar
  3. Hoover EA, Mullins JI. Feline leukemia virus infection and diseases. J Am Vet Med Assoc. 1991;199:1287–97.PubMedGoogle Scholar
  4. Hartmann K. Clinical aspects of feline retroviruses: a review. Viruses. 2012;4:2684–710.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Francis DP, Essex M, Hardy WD. Excretion of feline leukaemia virus by naturally infected pet cats. Nature. 1977;269:252–4.View ArticlePubMedGoogle Scholar
  6. Gomes-Keller MA, Tandon R, Gönczi E, Meli ML, Hofmann-Lehmann R, Lutz H. Shedding of feline leukemia virus RNA in saliva is a consistent feature in viremic cats. Vet Microbiol. 2006;112:11–21.View ArticlePubMedGoogle Scholar
  7. Gomes-Keller MA, Gönczi E, Grenacher B, Tandon R, Hofman-Lehmann R, Lutz H. Fecal shedding of infectious feline leukemia virus and its nucleic acids: a transmission potential. Vet Microbiol. 2009;134:208–17.View ArticlePubMedGoogle Scholar
  8. Reinacher M. Diseases associated with spontaneous feline leukemia virus (FeLV) infection in cats. Vet Immunol Immunopathol. 1989;21:85–95.View ArticlePubMedGoogle Scholar
  9. Driciru M, Siefert L, Prager KC, Dubovi E, Sande R, Princee F, Friday T, Munson L. A serosurvey of viral infections in lions (Panthera leo), from queen Elizabeth National Park, Uganda. J Wildl Dis. 2006;42:667–71.View ArticlePubMedGoogle Scholar
  10. Thalwitzer S, Wachter B, Robert N, Wibbelt G, Müller T, Lonzer J, Meli ML, Bay G, Hofer H, Lutz H. Seroprevalences to viral pathogens in free-ranging and captive cheetahs (Acinonyx jubatus) on Namibian Farmland. Clin Vaccine Immunol. 2010;17:232–8.View ArticlePubMedGoogle Scholar
  11. Ostrowski S, Van Vuuren M, Lenain DM, Durand A. A serologic survey of wild felids from central west Saudi Arabia. J Wildl Dis. 2003;39:696–701.View ArticlePubMedGoogle Scholar
  12. Filoni C, Adania CH, Durigon EL, Catão-Dias JL. Serosurvey for feline leukemia virus and lentiviruses in captive small neotropic felids in São Paulo state, Brazil. J Zoo Wildl Med. 2003;34:65–8.Google Scholar
  13. Hofmann-Lehmann R, Fehr D, Grob M, Elgizoli M, Packer C, Martenson JS, O’Brien SJ, Lutz H. Prevalence of antibodies to feline parvovirus, calicivirus, herpesvirus, coronavirus, and immunodeficiency virus and of feline leukemia virus antigen and the interrelationship of these viral infections in free-ranging lions in East Africa. Clin Diag Lab Immunol. 1996;3:554–62.Google Scholar
  14. Blanco K, Peña R, Hernández C, Jiménez M, Araya LN, Romero JJ, Dolz G. Serological detection of viral infections in captive wild cats from Costa Rica. Vet Med. 2011; https://doi.org/10.4061/2011/879029. Internat 879029
  15. Leutenegger CM, Mislin CN, Sigrist B, Ehrengruber MU, Hofmann-Lehmann R, Lutz H. Viral infections in free-living populations of the European wildcat. J Wildl Dis. 1999;35:678–86.View ArticlePubMedGoogle Scholar
  16. Daniels MJ, Golder MC, Jarrett O, MacDonald DW. Feline viruses in wildcats from Scotland. J Wildl Dis. 1999;35:121–4.View ArticlePubMedGoogle Scholar
  17. Fromont E, Sager A, Léger F, Bourguemestre F, Jouquelet E, Stahl P, Pontier D, Artois M. Prevalence and pathogenicity of retroviruses in wildcats in France. Vet Rec. 2000;146:317–9.View ArticlePubMedGoogle Scholar
  18. Meli ML, Cattori V, Martínez F, López G, Vargas A, Palomares F, López-Bao JV, Hofmann-Lehmann R, Lutz H. Feline leukemia virus and other pathogens as important threats to the survival of the critically endangered Iberian lynx (Lynx pardinus). PLoS One. 2009;4(3):e4744. https://doi.org/10.1371/journal.pone.0004744.
  19. Marina ML, Cattori V, Martínez F, López G, Vargas A, Palomares F, López-Bao JV, Hofmann-Lehmann R, Lutz H. Feline leukemia virus infection: a threat for the survival of the critically endangered Iberian lynx (Lynx pardinus). Vet Immunol Immunopathol. 2010;134:61–7.View ArticleGoogle Scholar
  20. Cunningham MW, Brown MA, Shindle DB, Terrell SP, Hayes KA, Ferree BC, McBride RT, Blankenship EL, Jansen D, Citino SB, Roelke ME, Kiltie RA, Troyer JL, O’Brien SJ. Epizootiology and management of feline leukemia virus in the Florida puma. J Wildl Dis. 2008;44:537–52.Google Scholar
  21. Brown MA, Cunningham MW, Roca AL, Troyer JL, Johnson WE, O’Brien SJ. Genetic characterization of feline leukemia virus from Florida panthers. Emerg Infect Dis. 2008;14:252–9.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Guimaraes AMS, Brandão PE, de Moraes W, Cubas ZS, Santos LC, Villarreal LYB, Robes RR, Coelho FM, Resende M, Santos RCF, Oliveira RC, Yamaguti M, Marques LM, Neto RL, Buzinhani M, Marques R, Messick JB, Biondo AW, Timenetsky J. Survey of feline leukemia virus and feline coronaviruses in captive neotropical wild felids from southern Brazil. J Zoo Wildl Med. 2009;40:360–4.View ArticlePubMedGoogle Scholar
  23. Filoni C, Catão-Dias JL, Cattori V, Willi B, Meli ML, Corrêa SHR, Marques MC, Adania CH, Silva JCR, Marvulo MFV, Neto JSF, Durigon EL, Carvalho VM, Coutinho SD, Lutz H, Hofmann-Lehmann R. Surveillance using serological and molecular methods for the detection of infectious agents in captive Brazilian neotropic and exotic felids. J Vet Diagn Investig. 2012;24:166–73.View ArticleGoogle Scholar
  24. Filoni C, Catão-Dias JL, Bay G, Durigon EL, Jorge RS, Lutz H, Hofmann-Lehmann R. First evidence of feline herpesvirus, calicivirus, parvovirus, and Ehrlichia exposure in Brazilian free-ranging felids. J Wildl Dis. 2006;42:470–7.View ArticlePubMedGoogle Scholar
  25. Hofmann-Lehmann R, Cattori V, Tandon R, Boretti FS, Meli ML, Riond B, Lutz H. How molecular methods change our views of FeLV infection and vaccination. Vet Immunol Immunopathol. 2008;123:119–123.Google Scholar
  26. Hofmann-Lehmann R, Cattori V, Tandon R, Boretti FS, Meli ML, Riond B, Pepin AC, Willi B, Ossent P, Lutz H. Vaccination against the feline leukaemia virus: outcome and response categories and long-term follow-up. Vaccine. 2007;25:5531–9.View ArticlePubMedGoogle Scholar
  27. Major A, Cattori V, Boenzli E, Riond B, Ossent P, Meli ML, Hofmann-Lehmann R, Lutz H. Exposure of cats to low doses of FeLV: seroconversion as the sole parameter of infection. Vet Res. 2010;41:17.View ArticlePubMedGoogle Scholar
  28. Torres AN, Mathiason CK, Hoover EA. Re-examination of feline leukemia virus: host relationships using real-time PCR. Virology. 2005;332:272–83.View ArticlePubMedGoogle Scholar
  29. Cattori V, Pepin AC, Tandon R, Riond B, Meli ML, Willi B, Lutz H, Hofmann-Lehmann R. Real-time PCR investigation of feline leukemia virus proviral and viral RNA loads in leukocyte subsets. Vet Immunol Immunopathol. 2008;123:124–8.View ArticlePubMedGoogle Scholar
  30. Tandon R, Cattori V, Gomes-Keller MA, Meli ML, Golder MC, Lutz H, Hofmann-Lehmann R. Quantitation of feline leukaemia virus viral and proviral loads by TaqMan real-time polymerase chain reaction. J Virol Methods. 2005;130:124–32.View ArticlePubMedGoogle Scholar
  31. Pepin AC, Tandon R, Cattori V, Niederer E, Riond B, Willi B, Lutz H, Hofmann-Lehmann R. Cellular segregation of feline leukemia provirus and viral RNA in leukocyte subsets of long-term experimentally infected cats. Virus Res. 2007;127:9–16.View ArticlePubMedGoogle Scholar
  32. Boenzli E, Hadorn M, Hartnack S, Huder J, Hofmann-Lehmann R, Lutz H. Detection of antibodies to the feline leukemia virus (FeLV) transmembrane protein p15E: an alternative approach for serological FeLV detection based on antibodies to p15E. J Clin Microbiol. 2014;52:2046–52.Google Scholar
  33. Nesina S, Helfer-Hungerbuehler AK, Riond B, Boretti FS, Willi B, Meli ML, Grest P, Hofmann-Lehmann R. Retroviral DNA - the Silent Winner: Blood Transfusion Containing Latent Feline Leukemia Provirus Causes Infection and Disease in Naïve recipient cats. Retrovirology 12. BioMed Central. 2015;105 https://doi.org/10.1186/s12977-015-0231-z.
  34. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577–80.View ArticlePubMedGoogle Scholar
  35. Kipar A, Kremendahl J, Grant CK, von Bothmer I, Reinacher M. Expression of viral proteins in feline leukemia virus-associated enteritis. Vet Pathol. 2000;37:129–36.View ArticlePubMedGoogle Scholar
  36. Helfer-Hungerbuehler AK, Widmer S, Hofmann-Lehmann R. GAPDH pseudogenes and the quantification of feline genomic DNA equivalents. Mol Biol Internat. 2013;587680 https://doi.org/10.1155/2013/587680.
  37. Kessler Y, Helfer-Hungerbuehler AK, Cattori V, Meli ML, Zellweger B, Ossent P, Riond B, Reusch CE, Lutz H, Hofmann-Lehmann R. Quantitative TaqMan real-time PCR assays for gene expression normalisation in feline tissues. BMC Mol Biol. 2009;10:106. https://doi.org/10.1186/1471-2199-10-106.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Leutenegger CM, Mislin CN, Sigrist B, Ehrengruber MU, Hofmann-Lehmann R, Lutz H. Quantitative real-time PCR for the measurement of feline cytokine mRNA. Vet Immunol Immunopathol. 1999;71:291–305.View ArticlePubMedGoogle Scholar
  39. Sheets RL, Pandey R, Jen WC, Roy-Burman P. Recombinant feline leukemia virus genes detected in naturally occurring feline lymphosarcomas. J Virol. 1993;67:3118–25.PubMedPubMed CentralGoogle Scholar
  40. Mathes LE, Pandey R, Chakrabarti R, Hofman FM, Hayes KA, Stromberg P, Roy-Burman P. Pathogenicity of a subgroup C feline leukemia virus (FeLV) is augmented when administered in association with certain FeLV recombinants. Virology. 1994;198:185–95.View ArticlePubMedGoogle Scholar
  41. Lutz H, Arnold P, Hübscher U, Egberink H, Pedersen N, Horzinek MC. Specificity assessment of feline T-lymphotropic lentivirus serology. Zentralbl Veterinarmed B. 1988;35:773–8.PubMedGoogle Scholar
  42. Allenspach K, Amacker M, Leutenegger CM, Hottiger M, Hofmann-Lehmann R, Hübscher U, Pistello M, Lutz H. Quantification of proviral FIV DNA using competitive PCR. Schweiz Arch Tierheilkd. 1996;138:87–92.PubMedGoogle Scholar
  43. Klein D, Leutenegger CM, Bahula C, Gold P, Hofmann-Lehmann R, Salmons B, Lutz H, Gunzburg WH. Influence of preassay and sequence variations on viral load determination by a multiplex real-time reverse transcriptase-polymerase chain reaction for feline immunodeficiency virus. J Acquir Immune Defic Syndr. 2001;26:8–20.View ArticlePubMedGoogle Scholar
  44. Tandon R, Cattori V, Willi B, Lutz H, Hofmann-Lehmann R. Association between endogenous feline leukemia virus loads and exogenous feline leukemia virus infection in domestic cats. Virus Res. 2008;135:136–43.View ArticlePubMedGoogle Scholar
  45. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol. 2013;30:2725–9.View ArticlePubMedPubMed CentralGoogle Scholar
  46. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673–80.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987;4:406–25.PubMedGoogle Scholar
  48. Nei M, Kumar S. Phylogenetic inference: maximum parsimony methods. In: Nei M, Kumar S, editors. Molecular evolution and Phylogenetics. New York: Oxford University Press Inc.; 2000.Google Scholar
  49. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution. 1985;39:783–91.View ArticlePubMedGoogle Scholar
  50. Hofmann-Lehmann R, Huder JB, Gruber S, Boretti F, Sigrist B, Lutz H. Feline leukaemia provirus load during the course of experimental infection and in naturally infected cats. J Gen Virol. 2001;82:1589–96.View ArticlePubMedGoogle Scholar
  51. Helfer-Hungerbuehler AK, Widmer S, Kessler Y, Riond B, Boretti FS, Grest P, Lutz H, Hofmann-Lehmann R. Long-term follow up of feline leukemia virus infection and characterization of viral RNA loads using molecular methods in tissues of cats with different infection outcomes. Virus Res. 2015;197:137–50.View ArticlePubMedGoogle Scholar
  52. Johnson WE, Eizirik E, Pecon-Slattery J, Murphy WJ, Antunes A, Teeling E, O’Brien SJ. The late Miocene radiation of modern Felidae: a genetic assessment. Science. 2006;311:73–7.View ArticlePubMedGoogle Scholar
  53. Hartmann K. Clinical aspects of feline immunodeficiency and feline leukemia virus infection. Vet Immunol Immunopathol. 2011;143:190–201.View ArticlePubMedGoogle Scholar
  54. Marker L, Munson L, Basson PA, Quackenbush S. Multicentric T-cell lymphoma associated with feline leukemia virus infection in a captive Namibian cheetah (Acinonyx jubatus). J Wildl Dis. 2003;39:690–5.View ArticlePubMedGoogle Scholar
  55. Harrison TM, McKnight CA, Sikarskie JG, Kitchell BE, Garner MM, Raymond JT, Fitzgerald SD, Valli VE, Agnew D, Kiupel M. Malignant lymphoma in African lions (Panthera leo). Vet Pathol. 2010;47:952–7.View ArticlePubMedGoogle Scholar
  56. Kaye S, Wang W, Miller C, McLuckie A, Beatty JA, Grant CK, VandeWoude S, Bielefeldt-Ohmann H. Role of feline immunodeficiency virus in lymphomagenesis - going alone or colluding? ILAR J. 2016;57:24–33.View ArticlePubMedGoogle Scholar
  57. Helfer-Hungerbuehler AK, Cattori V, Bachler B, Hartnack S, Riond B, Ossent P, Lutz H, Hofmann-Lehmann R. Quantification and molecular characterization of the feline leukemia virus A receptor. Infect Genet Evol. 2011;11:1940–50.View ArticleGoogle Scholar
  58. Roca AL, Pecon-Slattery J, O’Brien SJ. Genomically intact endogenous feline leukemia viruses of recent origin. J Virol. 2004;78:4370–5.View ArticlePubMedPubMed CentralGoogle Scholar
  59. Coelho FM, Bomfim MR, de Andrade CF, Ribeiro NA, Luppi MM, Costa EA, Oliveira ME, da Fonseca FG, Resende M. Naturally occurring feline leukemia virus subgroup A and B infections in urban domestic cats. J Gen Virol. 2008;89:2799–805.View ArticlePubMedGoogle Scholar
  60. Hoover EA, Mullins JI, Quackenbush SL, Gasper PW. Experimental transmission and pathogenesis of immunodeficiency syndrome in cats. Blood. 1987;70:1880–92.PubMedGoogle Scholar
  61. Donahue PR, Hoover EA, Beltz GA, Riedel N, Hirsch VM, Overbaugh J, Mullins JI. Strong sequence conservation among horizontally transmissible, minimally pathogenic feline leukemia viruses. J Virol. 1988;62:722–31.PubMedPubMed CentralGoogle Scholar
  62. Simon F, Cassaro K, Quillen P. Small felid breeding project at Sao Paulo zoo. Int Zoo Yearb. 1997;35:159–64.View ArticleGoogle Scholar
  63. Chandhasin C, Coan PN, Levy LS. Subtle mutational changes in the SU protein of a natural feline leukemia virus subgroup A isolate alter disease spectrum. J Virol. 2005;79:1351–60.View ArticlePubMedPubMed CentralGoogle Scholar
  64. Lehmann R, Franchini M, Aubert A, Wolfensberger C, Cronier J, Lutz H. Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine. J Am Vet Med Assoc. 1991;199:1446–52.PubMedGoogle Scholar
  65. Hofmann-Lehmann R, Holznagel E, Aubert A, Ossent P, Reinacher M, Lutz H. Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection. Vet Immunol Immunopathol. 1995;46:127–37.View ArticlePubMedGoogle Scholar
  66. Lutz H, Pedersen NC, Durbin R, Theilen GH. Monoclonal antibodies to three epitopic regions of feline leukemia virus p27 and their use in enzyme-linked immunosorbent assay of p27. J Immunol Methods. 1983;56:209–20.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement